Cyclotron Core

The Cyclotron Core was started to address the unmet needs of bringing investigational radiopharmaceuticals within patient reach. Few academic institutions have a cGMP-compliant cyclotron facility committed to manufacturing research radiopharmaceuticals. This unique situation attracts many investigators and industry sponsors aiming to provide clinical translation of promising radiopharmaceuticals, particularly in preclinical to early phase clinical trials. The Cyclotron Core collaborates with both the Nuclear Pharmacy and PET Imaging Core to provide unmatched translation of novel radiotracers into clinical practice. Additionally, the Cyclotron Core supports the Preclinical Imaging Core with radioisotopes and radiotracers.

Radiopharmaceuticals

FDA Approved for Hospital Clinical Use

  1. [18F] Fludeoxyglucose (Oncology) (multipurpose, diverse, all-purpose, universal, broad spectrum)
  2. [13N]- Ammonia (Cardiology) 
  3. [68Ga] DOTATOC (Oncology)*

 

*Pending FDA ANDA approval

FDA Approved for Research/Investigational Use

Due to proprietary reasons, many of our investigational radiopharmaceuticals are not listed and in varying clinical trial phases for cardiology, oncology, urology, and neurology. Here are a few currently produced radiotracers.

TOP